Baseline characteristics of patients enrolled
| . | HepB-CpG (n = 58) . | RZV (n = 63) . | ||
|---|---|---|---|---|
| . | TN (n = 32) . | BTKi (n = 26) . | TN (n = 22) . | BTKi (n = 41) . |
| Age, median (IQR), y | 65.0 (57.3-71.0) | 65.5 (57.8-71.0) | 66.5 (57.8-73.0) | 65.0 (58.5-72.5) |
| Sex, n (%) | ||||
| Female | 12 (37.5%) | 8 (30.8%) | 7 (31.8%) | 15 (36.6%) |
| Male | 20 (62.5%) | 18 (69.2%) | 15 (68.2%) | 26 (63.4%) |
| Disease/treatment status, n (%) | ||||
| Time from diagnosis, median (IQR), mo | 58 (25-121) | 104 (75-149) | 84 (40-120) | 95 (73-147) |
| Therapies before BTKi initiation | ||||
| 0 | — | 13 (50.0%) | — | 25 (61.0%) |
| 1 | — | 12 (46.2%) | — | 13 (31.7%) |
| 2 | — | 1 (3.8%) | — | 3 (7.3%) |
| Prior chemotherapy | — | 11 (42.3%) | — | 14 (34.1%) |
| Prior anti-CD20 monoclonal antibody | — | 11 (42.3%) | — | 14 (34.1%) |
| BTKi received | ||||
| Ibrutinib | — | 15 (25.9%) | — | 20 (31.7%) |
| Acalabrutinib | — | 11 (19.0%) | — | 21 (33.3%) |
| Duration on BTKi, median (IQR), mo | — | 45 (20-66) | — | 41 (19-65) |
| Best response to BTKi therapy | ||||
| Overall response rate (ORR) | — | 26 (100%) | — | 41 (100%) |
| Complete response (CR) | — | 5 (19.2%) | — | 8 (19.5%) |
| Laboratory parameters, median (IQR) | ||||
| Absolute lymphocyte count, k/µL | 23.0 (11.72-57.59) | 4.14 (1.86-7.33) | 36.25 (11.16-65.70) | 2.95 (1.74-7.33) |
| β-2-microglobulin, mg/L | 2.1 (1.7-2.4) | 2.0 (1.68-2.33) | 1.9 (1.6-2.5) | 2.0 (1.7-2.8) |
| Immunoglobulin G, mg/dL | 652 (535-782) | 474 (417-759) | 680 (498-866) | 507 (404-830) |
| . | HepB-CpG (n = 58) . | RZV (n = 63) . | ||
|---|---|---|---|---|
| . | TN (n = 32) . | BTKi (n = 26) . | TN (n = 22) . | BTKi (n = 41) . |
| Age, median (IQR), y | 65.0 (57.3-71.0) | 65.5 (57.8-71.0) | 66.5 (57.8-73.0) | 65.0 (58.5-72.5) |
| Sex, n (%) | ||||
| Female | 12 (37.5%) | 8 (30.8%) | 7 (31.8%) | 15 (36.6%) |
| Male | 20 (62.5%) | 18 (69.2%) | 15 (68.2%) | 26 (63.4%) |
| Disease/treatment status, n (%) | ||||
| Time from diagnosis, median (IQR), mo | 58 (25-121) | 104 (75-149) | 84 (40-120) | 95 (73-147) |
| Therapies before BTKi initiation | ||||
| 0 | — | 13 (50.0%) | — | 25 (61.0%) |
| 1 | — | 12 (46.2%) | — | 13 (31.7%) |
| 2 | — | 1 (3.8%) | — | 3 (7.3%) |
| Prior chemotherapy | — | 11 (42.3%) | — | 14 (34.1%) |
| Prior anti-CD20 monoclonal antibody | — | 11 (42.3%) | — | 14 (34.1%) |
| BTKi received | ||||
| Ibrutinib | — | 15 (25.9%) | — | 20 (31.7%) |
| Acalabrutinib | — | 11 (19.0%) | — | 21 (33.3%) |
| Duration on BTKi, median (IQR), mo | — | 45 (20-66) | — | 41 (19-65) |
| Best response to BTKi therapy | ||||
| Overall response rate (ORR) | — | 26 (100%) | — | 41 (100%) |
| Complete response (CR) | — | 5 (19.2%) | — | 8 (19.5%) |
| Laboratory parameters, median (IQR) | ||||
| Absolute lymphocyte count, k/µL | 23.0 (11.72-57.59) | 4.14 (1.86-7.33) | 36.25 (11.16-65.70) | 2.95 (1.74-7.33) |
| β-2-microglobulin, mg/L | 2.1 (1.7-2.4) | 2.0 (1.68-2.33) | 1.9 (1.6-2.5) | 2.0 (1.7-2.8) |
| Immunoglobulin G, mg/dL | 652 (535-782) | 474 (417-759) | 680 (498-866) | 507 (404-830) |